Nanox Launches AI Functionality In Second Opinions Online Medical Consultation Service
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service
New AI capabilities available to patients who submit chest and abdominal CT scans for second opinions
Offering the power of Artificial Intelligence to their second opinion CT report to promote early detection of chronic conditions
PETACH TIKVA, Israel, June 05, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company, NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., has launched an artificial intelligence (AI) functionality in the Second Opinions online medical consultation service. Second Opinions is a platform provided by USARAD Holdings INC, a subsidiary of Nano-X Imaging Ltd., that provides teleradiology services. The platform connects patients with radiologists and other subspecialty physicians for additional consultation on their medical diagnoses. Second Opinions has integrated three of Nanox.AI's FDA 510(k)-cleared AI solutions, enabling patients to conveniently get second opinions from experts in various medical and surgical subspecialties including radiology, neurology, oncology and orthopedic surgery. The integration of Nanox.AI's tools is intended to promote the early detection of chronic conditions on chest and abdominal CT scans:
- AI Cardiac solution (HealthCCSng) detects coronary artery calcium, an early sign of coronary artery disease
- AI Bone solution (HealthOST) assesses bone mineral density, and highlights vertebral spine compression fractures which can indicate risk of osteoporosis
- AI Liver solution (HealthFLD) measures liver density, which can indicate fatty liver disease